Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.52 |
| ▸ | DGKA | P23743 | 1/20 | 0.67 |
| ▸ | PAM | P19021 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | PPARD | Q03181 | 4/20 | 0.52 |
| ▸ | PPARA | Q07869 | 4/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6448229 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL989180 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL5395399 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Ethyl Tetradecanoate SCHEMBL8330964 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL173634 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL2213929 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL787652 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL3028566 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL543614 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Acetic Acid SCHEMBL8469053 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112930174-A | Methods for synthesizing D3 dopamine receptor agonists | 波利科尔疗法公司 | 2021-06-08 | — | — | CN | disclosed |
| US-8598123-B2 | Peptide analogues | PFIZER INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2539358-A1 | PEPTIDE ANALOGUES | Pfizer Limited (GB) | 2013-01-02 | — | — | EP | disclosed |
| US-20120329724-A1 | PEPTIDE ANALOGUES | PFIZER LIMITED | 2012-12-27 | — | — | US | disclosed |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| CN-102753184-A | Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases | SANOFI AVENTIS | 2012-10-24 | — | — | CN | disclosed |
| EP-2482823-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI (FR) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011104649-A1 | PEPTIDE ANALOGUES | PFIZER LIMITED (GB) | 2011-09-01 | — | — | WO | disclosed |
| US-20110207654-A1 | PEPTIDE ANALOGUES | PFIZER INC. | 2011-08-25 | — | — | US | disclosed |
| WO-2011039338-A2 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES | SANOFI-AVENTIS (FR) | 2011-04-07 | — | — | WO | disclosed |
| US-5574164-A | 1-alkyl-,1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds | HOESCHT ROUSSEL PHARMACEUTICALS INC. (US) | 1996-11-12 | — | — | US | disclosed |
| US-5571923-A | 3-/1-DODECYL/-5-ISOXAZOLEMETHANOL INTERMEDIATE | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-11-05 | — | — | US | disclosed |
| US-5565584-A | CHEMICAL INTERMEDIATES | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| US-5557006-A | 1-Alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-09-17 | — | — | US | disclosed |
| US-5550247-A | ANTIINFLAMMATORY AGENT, ANTITUMOR AGENT, COGNITION ACTIVATORS, BACTERICIDES, FUNGICIDES | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1996-08-27 | — | — | US | disclosed |
| US-5534640-A | REDUCING INFLAMMATION AND CELL PROLIFERATION, COGNITION ACTIVATORS, BACTERIOSTATS, FUNGISTATS | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5534636-A | ANTIINFLAMMATORY AGENTS, ANTITUMOR AGENT, COGNITION ACTIVATORS,BACTERICIDES, AND FUNGICIDES | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5519062-A | ANTIINFLAMMATORY | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-05-21 | — | — | US | disclosed |
| US-5488063-A | ANTIINFLAMMATORY, ANTICARACINOGENIC AGENTS; BACTERICIDES, FUNGICIDES | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-01-30 | — | — | US | disclosed |
| US-5488061-A | ANTIINFLAMMATORY, ANTICARACINOGENIC AGENTS; BACTERICIDES, FUNGICIDES | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1996-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329724-A1 | PEPTIDE ANALOGUES | OPRL1, OGFR, OPRM1 | ESR1 978/4885DGKA 3870/4885PAM 257/4885 |
| US-20120270819-A1 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE | SLC5A1, SLC5A2, SOST | ESR1 675/4885DGKA 1930/4885PAM 1781/4885 |
| US-20110207654-A1 | PEPTIDE ANALOGUES | OPRL1, OGFR, OPRM1 | ESR1 978/4885DGKA 3870/4885PAM 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.